Xiangbao Meng Selected Research

hypoglycemic encephalopathy

1/2019	Notoginsenoside R1 Ameliorates Diabetic Retinopathy through PINK1-Dependent Activation of Mitophagy.
12/2018	Gastrodin Alleviates Cognitive Dysfunction and Depressive-Like Behaviors by Inhibiting ER Stress and NLRP3 Inflammasome Activation in db/db Mice.
2/2018	Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db/db Mice.
2/2018	Notoginsenoside R1 ameliorates diabetic encephalopathy by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiangbao Meng Research Topics

Disease

12	Neoplasms (Cancer) 12/2024 - 01/2012
8	Brain Ischemia (Cerebral Ischemia) 10/2023 - 01/2018
7	Reperfusion Injury 10/2023 - 01/2018
7	Insulin Resistance 02/2023 - 07/2017
6	Alzheimer Disease (Alzheimer's Disease) 02/2023 - 08/2014
5	Inflammation (Inflammations) 01/2019 - 01/2018
4	Cognitive Dysfunction 03/2022 - 01/2018
4	hypoglycemic encephalopathy 01/2019 - 02/2018
3	Neuroinflammatory Diseases 10/2023 - 01/2021
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 03/2023 - 01/2018
3	Ischemic Stroke 03/2023 - 12/2018
3	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2018
3	Colonic Neoplasms (Colon Cancer) 03/2019 - 06/2017
2	Hypoxia (Hypoxemia) 03/2023 - 01/2013
2	Diabetic Retinopathy (Retinopathy, Diabetic) 02/2020 - 01/2019
2	Body Weight (Weight, Body) 10/2019 - 12/2018
2	Infarction (Infarctions) 01/2019 - 01/2018
2	Central Nervous System Diseases (CNS Diseases) 01/2019 - 12/2018
2	Hemorrhage 12/2018 - 02/2018
2	Necrosis 12/2018 - 01/2018
2	Dyslipidemias (Dyslipidemia) 12/2018 - 01/2018
2	Sarcoma (Soft Tissue Sarcoma) 06/2017 - 01/2012
2	Cardiotoxicity 01/2016 - 01/2013
1	Colitis 08/2023
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2023
1	Cardiomegaly (Heart Hypertrophy) 01/2022
1	Heart Failure 01/2022
1	Fatty Liver 01/2020
1	Pneumoconiosis 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Depressive Disorder (Melancholia) 10/2019
1	Hyperlipidemias (Hyperlipidemia) 01/2019
1	Hypertension (High Blood Pressure) 01/2019
1	Obesity 01/2019

Drug/Important Bio-Agent (IBA)

10	Neuroprotective AgentsIBA 03/2023 - 01/2018
6	Glucose (Dextrose)FDA LinkGeneric 02/2023 - 01/2018
5	InflammasomesIBA 12/2018 - 01/2018
4	notoginsenoside R1IBA 01/2021 - 02/2018
3	TriterpenesIBA 03/2023 - 01/2019
3	NaphthalimidesIBA 10/2017 - 06/2014
2	Insulin (Novolin)FDA Link 02/2023 - 01/2019
2	15-deoxyprostaglandin J2IBA 01/2023 - 01/2021
2	gamma-Butyrobetaine DioxygenaseIBA 01/2022 - 01/2020
2	Carnitine (L-Carnitine)FDA LinkGeneric 01/2022 - 01/2020
2	N,N,N-trimethyl-5-aminovaleric acidIBA 01/2022 - 01/2020
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021 - 01/2018
2	SHP099IBA 01/2020 - 03/2019
2	Non-Receptor Type 11 Protein Tyrosine PhosphataseIBA 01/2020 - 03/2019
2	Antidepressive Agents (Antidepressants)IBA 10/2019 - 04/2018
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019 - 07/2017
2	Blood Glucose (Blood Sugar)IBA 01/2019 - 12/2018
2	Retinaldehyde (Retinal)IBA 01/2019 - 07/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 12/2018
2	AntioxidantsIBA 12/2018 - 01/2018
2	Heparin (Liquaemin)FDA LinkGeneric 12/2018 - 02/2018
2	gastrodinIBA 12/2018 - 01/2018
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 09/2018 - 01/2018
2	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 02/2018 - 02/2018
2	oxidized low density lipoproteinIBA 01/2018 - 01/2017
2	Topoisomerase InhibitorsIBA 10/2017 - 06/2017
2	LSS-11IBA 10/2017 - 06/2017
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016 - 01/2013
1	Doublecortin-Like KinasesIBA 12/2024
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2024
1	Biomarkers (Surrogate Marker)IBA 12/2024
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 11/2023
1	scutellarinIBA 10/2023
1	Mitogen-Activated Protein KinasesIBA 10/2023
1	Proteolysis Targeting ChimeraIBA 10/2023
1	Mitogen-Activated Protein Kinase 7IBA 10/2023
1	CateninsIBA 08/2023
1	NAD (NADH)IBA 03/2023
1	gypenoside LXXVIBA 02/2023
1	antineoplaston A10 (A 10)IBA 03/2022
1	Glucagon-Like Peptide 1 (GLP 1)IBA 03/2022
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 03/2022
1	Dipeptidyl-Peptidase IV InhibitorsIBA 03/2022
1	AcidsIBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	trimethyllysineIBA 01/2022
1	Phytoestrogens (Phytoestrogen)IBA 01/2021
1	Nonesterified Fatty Acids (NEFA)IBA 01/2020
1	Silicon Dioxide (Silica)FDA LinkGeneric 01/2020
1	Interleukin-18 (Interleukin 18)IBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	Coal (Coals)IBA 01/2020
1	Sucrose (Saccharose)IBA 10/2019
1	Tyrosine (L-Tyrosine)FDA Link 03/2019
1	Granzymes (Granzyme)IBA 03/2019
1	Complement System Proteins (Complement)IBA 03/2019
1	GlycolipidsIBA 01/2019
1	ginsenoside Rb1IBA 01/2019
1	Interleukin-1 (Interleukin 1)IBA 01/2019
1	SaponinsIBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2019

Therapy/Procedure

4	Therapeutics 01/2018 - 01/2013
3	Immunotherapy 03/2019 - 01/2018
1	Drug Therapy (Chemotherapy) 12/2024
1	Transplantation 01/2022
1	Intranasal Administration 01/2021